REVTORPYK is a big leap forward in the treatment of HR+/HER2- breast cancer, inhibiting all 3 components of a critical pathway. Unleashing the power of PAM pathway inhibition has demonstrated unprecedented mPFS results in a patient population that desperately needed it. Approval anticipated April 2026.
